BNXTF

Quote

Short

News

Articles

Message Board

BioNxt Solutions Inc (OTCMKTS : BNXTF ) News

BioNxt Solutions Inc (OTCMKTS: BNXTF) News Releases

BNXTF News Releases

May 19, 2026 03:05:00 am

ACCESS Newswire

BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development

April 28, 2026 03:05:00 am

ACCESS Newswire

BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum

April 14, 2026 03:05:00 am

ACCESS Newswire

BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)

April 07, 2026 03:05:00 am

ACCESS Newswire

BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries

March 30, 2026 03:05:00 am

ACCESS Newswire

BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy

March 24, 2026 05:10:00 am

ACCESS Newswire

BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform

March 17, 2026 03:05:00 am

ACCESS Newswire

BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe

February 26, 2026 07:00:00 pm

ACCESS Newswire

BioNxt Announces Closing of Shares for Debt Settlement

September 05, 2025 03:05:00 am

ACCESS Newswire

BioNxt Solutions Completes Up-Listing to The OTCQB Market

September 02, 2025 03:05:00 am

ACCESS Newswire

Semaglutide API Delivery Enables Start of Lab-Scale ODF Development at BioNxt

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account